MX387296B - Proliferacion ex vivo de celulas epiteliales. - Google Patents

Proliferacion ex vivo de celulas epiteliales.

Info

Publication number
MX387296B
MX387296B MX2017012206A MX2017012206A MX387296B MX 387296 B MX387296 B MX 387296B MX 2017012206 A MX2017012206 A MX 2017012206A MX 2017012206 A MX2017012206 A MX 2017012206A MX 387296 B MX387296 B MX 387296B
Authority
MX
Mexico
Prior art keywords
epithelial cells
vivo proliferation
proliferation
vivo
compositions
Prior art date
Application number
MX2017012206A
Other languages
English (en)
Other versions
MX2017012206A (es
Inventor
Chengkang Zhang
Original Assignee
Propagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propagenix Inc filed Critical Propagenix Inc
Publication of MX2017012206A publication Critical patent/MX2017012206A/es
Publication of MX387296B publication Critical patent/MX387296B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para la proliferación y expansión ex vivo de células epiteliales.
MX2017012206A 2015-04-03 2016-03-31 Proliferacion ex vivo de celulas epiteliales. MX387296B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562142851P 2015-04-03 2015-04-03
US201562217406P 2015-09-11 2015-09-11
US201662294896P 2016-02-12 2016-02-12
PCT/US2016/025396 WO2016161192A1 (en) 2015-04-03 2016-03-31 Ex vivo proliferation of epithelial cells

Publications (2)

Publication Number Publication Date
MX2017012206A MX2017012206A (es) 2018-01-24
MX387296B true MX387296B (es) 2025-03-11

Family

ID=55806770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012206A MX387296B (es) 2015-04-03 2016-03-31 Proliferacion ex vivo de celulas epiteliales.

Country Status (12)

Country Link
US (7) US10119121B2 (es)
EP (2) EP3277799B1 (es)
JP (2) JP6964068B2 (es)
KR (1) KR102598772B1 (es)
CN (1) CN107636149A (es)
AU (1) AU2016243750B2 (es)
CA (1) CA2981708C (es)
DK (1) DK3277799T3 (es)
IL (1) IL254588B (es)
MX (1) MX387296B (es)
SG (2) SG10201902872YA (es)
WO (1) WO2016161192A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
KR102598772B1 (ko) 2015-04-03 2023-11-03 프로파제닉스 인크. 상피 세포의 생체외 증식
EP3892718A1 (en) 2015-09-11 2021-10-13 Propagenix Inc. Ex vivo proliferation of epithelial cells
JP6916318B2 (ja) * 2017-06-30 2021-08-11 ステムラボ・インコーポレイテッド 尿細胞からケラチノサイト幹細胞への直接逆分化方法および逆分化したケラチノサイト幹細胞を利用した皮膚再生促進用組成物の製造方法
US12303498B2 (en) 2018-03-23 2025-05-20 Cytoo ALK5 inhibitors as skeletal muscle hypertrophy inducers
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
EP3841195A1 (en) * 2018-08-20 2021-06-30 Propagenix Inc. Epithelial cell spheroids
KR20200032830A (ko) * 2018-09-19 2020-03-27 메디칸(주) 자가 줄기세포의 자가 배양 방법 및 장치
JP2022504202A (ja) 2018-10-03 2022-01-13 ステムバイオシス インコーポレイテッド 羊水細胞由来細胞外マトリックスおよびその使用
CN109294972A (zh) * 2018-10-17 2019-02-01 南京农业大学 一种羔羊小肠上皮细胞体外培养方法
US11047849B2 (en) * 2018-10-17 2021-06-29 Mandom Corporation Method for observing sebaceous gland and use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR102639023B1 (ko) 2019-02-21 2024-02-20 스템바이오시스, 인크. 양수 세포-유래 ecm 상에서 심근세포 성숙을 위한 방법, 세포 구조, 및 약물 화합물의 심장 독성 및 전부정맥 스크리닝을 위한 용도
JP2022525616A (ja) * 2019-03-19 2022-05-18 ユン，キュソン 細胞サンプルの評価のための方法およびシステム
EP4041252A4 (en) * 2019-09-09 2023-11-01 The Regents Of The University Of Michigan DEVELOPMENT OF EMBRYO-LIKE TISSUE FROM STEM CELLS
CN113249325B (zh) * 2020-02-11 2023-02-17 合肥中科普瑞昇生物医药科技有限公司 食管鳞癌原代细胞的培养基及培养方法
WO2021203911A1 (zh) * 2020-04-09 2021-10-14 中国医学科学院阜外医院 用于心肌细胞冻存的组合物
EP4229181A4 (en) * 2020-10-19 2024-10-02 Tel HaShomer Medical Research Infrastructure and Services Ltd. URINE-DERIVED EPITHELIAL CELL CULTURES, NEPHROSPHEROIDS DERIVED THEREFROM AND METHODS OF PRODUCTION AND USE THEREOF
US12344862B2 (en) * 2020-11-03 2025-07-01 Korea Research Institute Of Bioscience And Biotechnology Human intestinal epithelium model and method for preparing same
CN115873797B (zh) * 2021-09-29 2024-08-13 北京干细胞与再生医学研究院 一种视网膜色素上皮细胞的扩增培养基及培养方法
CN114181889B (zh) * 2021-11-24 2023-10-10 中国人民解放军总医院 一种原代汗腺细胞条件培养基及原代汗腺细胞培养方法
JP2024542858A (ja) * 2021-12-16 2024-11-15 ステムセル テクノロジーズ カナダ インコーポレイテッド ケラチノサイトを増殖させるための組成物及び方法
WO2023217121A1 (zh) * 2022-05-10 2023-11-16 上海赛立维生物科技有限公司 含肾前体样细胞的生物制剂及其制备方法和应用
CN117503800B (zh) * 2024-01-04 2024-04-05 北京益华生物科技有限公司 一种胃黏膜上皮细胞提取液及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3716907A1 (de) 1987-05-20 1988-12-01 Battelle Institut E V Verfahren zur vermehrung von epithelialzellen
CA1335572C (en) 1988-05-23 1995-05-16 Yoon Sang Cho-Chung Derivatives of cyclic amp as treatment for cancer
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US7326570B2 (en) 2000-06-16 2008-02-05 The Regents Of The University Of California Induction of tubular morphogenesis using pleiotrophin
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
WO2003065999A2 (en) 2002-02-08 2003-08-14 University Of South Florida Proliferated cell lines and uses thereof
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
EP1500643A4 (en) 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co benzamidine
US20040058392A1 (en) 2002-09-17 2004-03-25 Kylix B.V. Use of novel stem cell markers for isolation of intestinal stem cells, and use of the intestinal stem cells thus obtained for the preparation of a therapeutical composition
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US20070010008A1 (en) * 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
JP4869068B2 (ja) 2003-06-19 2012-02-01 スミスクライン ビーチャム コーポレーション 化合物
PL1644009T3 (pl) 2003-06-23 2018-07-31 Telomerase Activation Sciences, Inc. Kompozycje do zwiększania aktywności telomerazy i leczenia zakażenia hiv
CA2530389A1 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
US8252591B2 (en) 2004-05-07 2012-08-28 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
EP1860180A4 (en) 2005-02-23 2009-03-11 Found Biomedical Res & Innov METHOD FOR THE AMPLIFICATION OF AN ENDOTHEL PREPARATION CELL IN VITRO
CN103361301A (zh) 2005-03-31 2013-10-23 斯丹姆涅恩有限公司 高度纯化来自羊膜的细胞群
WO2007030693A2 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US7989204B2 (en) 2006-04-28 2011-08-02 Viacyte, Inc. Hepatocyte lineage cells
WO2008009642A1 (en) 2006-07-17 2008-01-24 Novozymes A/S Cell culture media
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
ES2579909T3 (es) 2009-02-03 2016-08-17 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
US9752124B2 (en) * 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
GB201111244D0 (en) * 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8476081B2 (en) 2009-09-21 2013-07-02 Janssen Pharmaceutica Nv Assay for evaluating affinity and specificity of ligand-albumin binding
US9708582B2 (en) 2009-10-13 2017-07-18 Stemcell Technologies Inc. Method of differentiating stem cells
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2638149B1 (en) 2010-11-12 2019-05-15 Georgetown University Immortalization of epithelial cells and methods of use
WO2012173207A1 (ja) 2011-06-14 2012-12-20 独立行政法人理化学研究所 網膜細胞への分化誘導方法
EP2772534B1 (en) 2011-10-27 2019-09-18 National University Corporation Tokyo Medical and Dental University Culturing colorectal epithelial stem cells and transplanting colorectal epithelium
US9828583B2 (en) 2012-01-13 2017-11-28 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
WO2014078414A1 (en) 2012-11-13 2014-05-22 Joseph Wu Chemically defined production of cardiomyocytes from pluripotent stem cells
US9533013B2 (en) 2013-03-13 2017-01-03 University Of North Carolina At Chapel Hill Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
TW201522637A (zh) * 2013-03-15 2015-06-16 Jackson Lab 非胚胎幹細胞之單離及其用途
US10266807B2 (en) * 2013-04-03 2019-04-23 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
EP2828380B1 (en) 2013-04-03 2016-09-21 Tampereen Yliopisto Methods and media for differentiating eye cells
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
KR102598772B1 (ko) 2015-04-03 2023-11-03 프로파제닉스 인크. 상피 세포의 생체외 증식
EP3892718A1 (en) 2015-09-11 2021-10-13 Propagenix Inc. Ex vivo proliferation of epithelial cells

Also Published As

Publication number Publication date
KR102598772B1 (ko) 2023-11-03
DK3277799T3 (en) 2020-12-14
US20170029779A1 (en) 2017-02-02
SG11201707970XA (en) 2017-10-30
US10711250B2 (en) 2020-07-14
SG10201902872YA (en) 2019-04-29
JP2020120686A (ja) 2020-08-13
CA2981708A1 (en) 2016-10-06
US9963680B2 (en) 2018-05-08
MX2017012206A (es) 2018-01-24
KR20170134634A (ko) 2017-12-06
US20230416686A1 (en) 2023-12-28
AU2016243750B2 (en) 2022-02-03
CN107636149A (zh) 2018-01-26
EP3277799A1 (en) 2018-02-07
AU2016243750A1 (en) 2017-10-05
US9790471B2 (en) 2017-10-17
IL254588B (en) 2020-07-30
US20180002669A1 (en) 2018-01-04
WO2016161192A1 (en) 2016-10-06
US11680246B2 (en) 2023-06-20
US20180208899A1 (en) 2018-07-26
IL254588A0 (en) 2017-11-30
JP2018512890A (ja) 2018-05-24
EP3277799B1 (en) 2020-09-23
CA2981708C (en) 2024-09-10
EP3822339A1 (en) 2021-05-19
US20210032602A1 (en) 2021-02-04
US10711251B2 (en) 2020-07-14
US20170029780A1 (en) 2017-02-02
US20180208900A1 (en) 2018-07-26
US10119121B2 (en) 2018-11-06
JP6964068B2 (ja) 2021-11-10
HK1249919A1 (zh) 2018-11-16

Similar Documents

Publication Publication Date Title
MX387296B (es) Proliferacion ex vivo de celulas epiteliales.
ZA201904258B (en) Compositions and methods for epithelial stem cell expansion and culture
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
ZA201806132B (en) Methods and compositions relating to hematopoietic stem cell expansion
CO2017009514A2 (es) Derivados de sobetiroma
PL4074331T3 (pl) Kompozycje i sposoby internalizacji enzymów
PL3368658T3 (pl) Namnażanie komórek T gamma delta rezydujących w tkankach nie-krwiotwórczych i zastosowania tych komórek
UY35510A (es) ?composiciones y métodos para mejorar la estabilidad microbiana?.
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
TR201908418T4 (tr) Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
MX390739B (es) Composicion de hueso comprimido y metodo para usar la misma.
TW201612308A (en) Collector architecture layout design
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EP3389674A4 (en) CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF PREPARATION AND USE
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
MX2015016603A (es) Composiciones de corticosteroides.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
UY34457A (es) Composición de Nitazoxanida mejorada y proceso para prepararla
IES20140280A2 (en) Human targets II